Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 21 points (0.1%) at 16,093 as of Tuesday, Nov. 26, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,560 issues advancing vs. 1,331 declining with 131 unchanged.

The Drugs industry currently sits up 0.9% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Shire ( SHPG), down 1.1%, and GlaxoSmithKline ( GSK), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Alnylam Pharmaceuticals ( ALNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Alnylam Pharmaceuticals is up $1.76 (2.9%) to $61.73 on light volume. Thus far, 272,419 shares of Alnylam Pharmaceuticals exchanged hands as compared to its average daily volume of 762,500 shares. The stock has ranged in price between $59.84-$61.88 after having opened the day at $60.00 as compared to the previous trading day's close of $59.97.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Alnylam Pharmaceuticals has a market cap of $3.7 billion and is part of the health care sector. Shares are up 219.6% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Alnylam Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Alnylam Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Alnylam Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, ACADIA Pharmaceuticals ( ACAD) is up $1.12 (5.1%) to $23.04 on light volume. Thus far, 453,637 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $21.90-$23.04 after having opened the day at $21.93 as compared to the previous trading day's close of $21.92.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $2.0 billion and is part of the health care sector. Shares are up 380.4% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. Get the full ACADIA Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Forest Laboratories ( FRX) is up $0.46 (0.9%) to $51.65 on light volume. Thus far, 377,186 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $51.46-$52.06 after having opened the day at $52.05 as compared to the previous trading day's close of $51.19.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $13.9 billion and is part of the health care sector. Shares are up 46.0% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Forest Laboratories a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Forest Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists